RxDoctor Payments Data

Eric Wirtschafter, MD

Internal Medicine · Sylmar, CANPI 1659716876

Payments from drug & device makers

$1,297in general payments, 2019–2025

Across 14 payments — averaging $92.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$500
  • AstraZeneca$460
  • Genentech USA, Inc.$133
  • Servier Pharmaceuticals LLC$122
  • Lexicon Pharmaceuticals, Inc.$23
  • Bristol Myers Squibb$23
  • plus $36 from 2 others

What the payments were for

  • Consulting fees$50039%
  • Speaking & faculty fees$30023%
  • Food & beverage$41232%
  • Education$857%

General payments by program year

19
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,297 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$47,765
Medicare patients
18
Services billed
1,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide85$1,093,604
TagrissoOsimertinib Mesylate52$857,684
TukysaTucatinib22$527,712
IbrancePalbociclib15$230,159
NubeqaDarolutamide20$222,529
JakafiRuxolitinib Phosphate25$187,641
CalquenceAcalabrutinib Maleate12$172,372
PromactaEltrombopag Olamine15$126,161
AlvaizEltrombopag Choline26$114,665
XareltoRivaroxaban40$27,182
EliquisApixaban15$11,807
Abiraterone Acetate26$3,947
Imatinib Mesylate58$3,359
Anastrozole75$2,063
Hydroxyurea44$1,573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso, Calquence$460$1,030,05664 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Sylmar

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →